Erythrocytes Carotenoids after Astaxanthin Supplementation in Middle-Aged and Senior Japanese Subjects

Miyazawa, Taiki; Nakagawa, Kiyotaka; Kimura, Fumiko; Satoh, Akira; Miyazawa, Teruo

doi:10.5650/jos.60.495

Cited by 8 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After ingestion of single oral dose of 10 mg of astaxanthin and 100 mg over four-weeks there was a non-linear dose response and selective absorption of Z -isomers and the plasma elimination half-life was 52 (SD 40) h [ 83 ]. Erythrocyte astaxanthin and plasma carotenoids were significantly higher after twelve weeks of 3 mg/d of orally administered astaxanthin compared with 1 mg/d or placebo [ 84 , 85 ].…”

Section: Human Astaxanthin Studiesmentioning

confidence: 99%

Astaxanthin in Cardiovascular Health and Disease

2012

View full text Add to dashboard Cite

Oxidative stress and inflammation are established processes contributing to cardiovascular disease caused by atherosclerosis. However, antioxidant therapies tested in cardiovascular disease such as vitamin E, C and β-carotene have proved unsuccessful at reducing cardiovascular events and mortality. Although these outcomes may reflect limitations in trial design, new, more potent antioxidant therapies are being pursued. Astaxanthin, a carotenoid found in microalgae, fungi, complex plants, seafood, flamingos and quail is one such agent. It has antioxidant and anti-inflammatory effects. Limited, short duration and small sample size studies have assessed the effects of astaxanthin on oxidative stress and inflammation biomarkers and have investigated bioavailability and safety. So far no significant adverse events have been observed and biomarkers of oxidative stress and inflammation are attenuated with astaxanthin supplementation. Experimental investigations in a range of species using a cardiac ischaemia-reperfusion model demonstrated cardiac muscle preservation when astaxanthin is administered either orally or intravenously prior to the induction of ischaemia. Human clinical cardiovascular studies using astaxanthin therapy have not yet been reported. On the basis of the promising results of experimental cardiovascular studies and the physicochemical and antioxidant properties and safety profile of astaxanthin, clinical trials should be undertaken.

show abstract

Section: Human Astaxanthin Studiesmentioning

confidence: 99%

Astaxanthin in Cardiovascular Health and Disease

2012

View full text Add to dashboard Cite

show abstract

“…AX is also well-known for strongly inhibiting the accumulation of lipid peroxides resulting from lipid peroxidation chain reactions [ 17 , 18 ]. In biological environments, AX has been detected in lipid droplets [ 19 ], cell membranes [ 20 ], or bound to proteins [ 18 , 21 , 22 , 23 ], due to its highly lipophilic properties. In addition, the structure of AX, like several other xanthophylls, it is thought to span across phospholipid bilayers that form biological membranes [ 24 , 25 , 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Astaxanthin as a Novel Mitochondrial Regulator: A New Aspect of Carotenoids, beyond Antioxidants

Nishida

Nawaz

Hecht³

et al. 2021

Nutrients

View full text Add to dashboard Cite

Astaxanthin is a member of the carotenoid family that is found abundantly in marine organisms, and has been gaining attention in recent years due to its varied biological/physiological activities. It has been reported that astaxanthin functions both as a pigment, and as an antioxidant with superior free radical quenching capacity. We recently reported that astaxanthin modulated mitochondrial functions by a novel mechanism independent of its antioxidant function. In this paper, we review astaxanthin’s well-known antioxidant activity, and expand on astaxanthin’s lesser-known molecular targets, and its role in mitochondrial energy metabolism.

show abstract

“…These extraction procedures were conducted under subdued yellow light to minimize photo degradation of the carotenoids. A C30 carotenoid column 4.6 250 mm, 5 μm; YMC, Kyoto, Japan was used; the column was eluted using a binary gradient consisting of the following HPLC solvents: A, methanol/MTBE/water 83:15:2 v/v/v, containing 3.9 mmol/L ammonium acetate , and B, methanol/MTBE/ water 8:90:2 v/v/v, containing 2.6 mmol/L ammonium acetate 19,20 . The gradient profile was as follows: 0-12 min, 10-55 B linear; 12-20 min, 55-100 B linear; 20-25 min, 100 B; 25-27 min, 100-10 .…”

Section: Extraction and Determination Of Carotenoidsmentioning

confidence: 99%

“…After addition of 1 mL of 0.1 mol/L aqueous sodium dodecyl sulfate, the sample was mixed with 12 mL of hexane/dichloromethane 5:1, v/v, containing 2.4 mmol/L butylated hydroxytoluene for extraction of erythrocyte carotenoids. The extract was purified with a Sep-Pak silica cartridge Waters, Milford, MA , and then subjected to HPLC coupled with UV detection 8,19,20 . These extraction procedures were conducted under subdued yellow light to minimize photo degradation of the carotenoids.…”

Section: Extraction and Determination Of Carotenoidsmentioning

confidence: 99%